 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
GUILFORD PHARM, (GLFD) Stock Rating Learn More
| Our Overall Rating on GUILFORD PHARM, GLFD is Not Available | | Guilford Pharmaceuticals, Inc. engages in the research, development, and commercialization of proprietary pharmaceutical products for the hospital and neurology markets. The company markets Gliadel Wafer and Aggrastat Injection products. Gliadel Wafer provides targeted, site-specific chemotherapy for the treatment of malignant glioma at the time of initial surgery and for the treatment of recurrent glioblastoma multiforme in conjunction with surgery and radiation. Aggrastat Injection is an inhibitor of platelet aggregation approved for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty. The companys product pipeline consists of AQUAVAN, GPI 1485, and DOPASCAN Injection, which are in various stages of clinical development. AQUAVAN is a prodrug of propofol for procedural sedation during brief diagnostic or therapeutic procedures. GPI 1485, a phase II clinical trial product, is a clinical candidate for the treatment of Parkinsons disease and postprostatectomy erectile dysfunction, as well as a preclinical development product for HIV-related dementia and neuropathy. DOPASCAN Injection is an imaging agent used to diagnose and monitor the progression of Parkinsons disease. Guilford Pharmaceuticals preclinical research programs include the development of NAALADase inhibitors for the treatment of neuropathic pain and peripheral neuropathy; PARP inhibitors for cancer chemo-and radiosensitization; and GPI 15715 in a non-intravenous formulation of the prodrug of propofol. Guilford was founded in 1993 by Solomon H. Snyder and Craig R. Smith. The company is headquartered in Baltimore, Maryland. | | Our Not Available Rating on GLFD was issued on 12/02/2008 |
GUILFORD PHARM Technical Rating
|
|
|
|
